Erratum to "EMAS position statement: Managing the menopause in the context of coronary heart disease" (Maturitas (2011) 68, (94-97) DOI: 10.1016/j.maturitas.2010.10.005);EMAS position statement: Managing the menopause in the context of coronary heart disease

Maturitas

Volumn 68, Issue 1, 2011, Pages 94-97

  Schenck Gustafsson, Karin ^a   Brincat, Mark ^a   Erel, C Tamer ^a   Gambacciani, Marco ^a   Lambrinoudaki, Irene ^a   Moen, Mette H ^a   Tremollieres, Florence ^a   Rozenberg, Svetlana Vujovic Serge ^a   Rees, Margaret ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Coronary heart disease; Menopause hormone therapy; Primary and secondary prevention

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; CAFFEINE; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GABAPENTIN; GESTAGEN; ISOFLAVONE DERIVATIVE; LUBRICATING AGENT; MEDROXYPROGESTERONE ACETATE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PROGESTERONE; RALOXIFENE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TIBOLONE; VENLAFAXINE;

ACUPUNCTURE; ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CIMICIFUGA RACEMOSA; DEMENTIA; FOLLOW UP; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUMIDIFIER; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MENOPAUSAL SYNDROME; MENOPAUSE; MORBIDITY; MORTALITY; NIGHT SWEAT; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIMARY PREVENTION; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK; RISK FACTOR; SECONDARY PREVENTION; SMOKING CESSATION; SOYBEAN; STROKE; VENOUS THROMBOEMBOLISM;

EID: 78650594819     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.03.006     Document Type: Erratum

References (46)

1. World Health Organization Statistical Information System; 2008. www.who.int/whosis (accessed 14 October 2010).
2. Swedish Board of Health and Welfare. Open comparisons; 2009 http://www.fhi.se/en/Publications/All-publications-in-english/ Open-Comparisons-2009 Public-Health-including-the-indicator-Smoking-habits/ (accessed 14 October 2010).
3. M. DesMeules, D. Manuel, and R. Cho Mortality: life and health expectancy of Canadian women, Women's Health Surveillance Report BMC Women's Health 4 Suppl. 1 2004 S9 10.1186/1472-6874-4-S1-S9
4. M. Stramba-Badiale European Heart Health Strategy. Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project Eur Heart J 31 2010 1677 1681
5. C. Melloni, J.S. Berger, and T.Y. Wang Representation of women in randomized clinical trials of cardiovascular disease prevention Circ Cardiovasc Qual Outcomes 3 2010 135 142
6. WHO Statistical Information System (WHOSIS); 1960. www.who.int/whosis (accessed 14 October 2010)
7. S. Yusuf, S. Hawken, and S. Ounpuu INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 9438 2004 937 952 (Pubitemid 39208455)
8. S.S. Anand, S. Islam, and A. Rosengren INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study Eur Heart J 29 2008 932 940
9. K. Schenck-Gustafsson Risk factors for cardiovascular disease in women Maturitas 63 2009 186 1890
10. S. Vujovic, M. Brincat, and T. Erel EMAS position statement: Managing women with premature ovarian failure Maturitas 67 2010 91 93
11. Drost JT, Maas AHEM, van Eyck J, van der Schouw YT. Preeclampsia as a female-specific risk factor for chronic hypertension Maturitas; 2010 sep 10. (Epub ahead of print) PMID 20833489-as supplied by publisher.
12. L.J. Shaw, C.N. Bairey Merz, and R. Azziz Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation J Clin Endocrinol Metab 93 4 2008 1276 1284
13. Alternatives to HRT for the Management of Symptoms of the Menopause (SAC Opinion Paper 6). RCOG; 2010. http://www.rcog.org.uk/womens-health/clinical- guidance/alternatives-hrt-management-symptoms-menopause (accessed 14 October 2010).
14. J.L. Shifren, and I. Schiff Role of hormone therapy in the management of menopause Obstet Gynecol 115 2010 839 855
15. S.R. Cummings, B. Ettinger, and P.D. Delmas LIFT Trial Investigators: the effects of tibolone in older postmenopausal women N Engl J Med 359 2008 697 708
16. E. Barrett-Connor, L. Mosca, and P. Collins Raloxifene use for The Heart (RUTH) Trial Investigators: effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137
17. L. Mosca, P. Collins, and D. Herrington Hormone replacement therapy and cardiovascular disease a statement for healthcare professionals from the American Heart Association Circulation 104 2001 499 503 (Pubitemid 32678285)
18. P. Collins, G. Rosano, and C. Casy Management of the cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynecologists Eur Heart J 28 2007 2028 2040 (Pubitemid 47579557)
19. M.J. Stampfer, G.A. Colditz, and W.C. Willett Postmenopausal estrogen therapy and cardiovascular disease Ten-year follow-up from the nurses' health study N Engl J Med 325 1991 756 762
20. E. Lökkegaard, A.H. Andreasson, and R.K. Jacobsen Hormone therapy and risk of myocardial infarction: a national register study Eur Heart J 29 2008 2660 2668
21. M.E. Mendelsohn, and R.H. Karas The protective effects of estrogen on the cardiovascular system N Engl J Med 340 1999 1801 1811
22. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
23. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
24. J.E. Manson, J. Hsia, and K.C. Johnson Women's Health Initiative Investigators Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
25. M. Hellgren, J. Conard, and L. Norris Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone Maturitas 62 2009 287 293
26. J. Hsia, R.D. Langer, and J.E. Manson Conjugated equine estrogens and coronary heart disease Arch Intern Med 166 2006 357 365
27. J.E. Manson, M.A. Allison, and J.A. Roussow For the WHI and WHI-CACS investigators estrogen therapy and coronary-artery calcification N Engl J Med 356 2007 2591 2602
28. J.E. Rossouw, R.L. Prentice, and J.E. Manson Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477
29. R.L. Prentice, J.E. Manson, and R.D. Langer Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause Am J Epidemiol 170 2009 12 23
30. T. Sengwee, S. Hernandes-Dias, and R. Logan Coronary heart disease in postmenopausal recipientsof estrogens plus progestin therapy: does the increased risk ever disappear? Ann Intern Med 152 2010 211 217
31. M. Canonico, G. Plu-Bureau, and G.D. Lowe Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis BMJ 336 7655 2008 1227 1231
32. V.M. Miller, D.M. Black, and E.A. Brinton Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) J Cardiovasc Transl Res 2 2009 228 239
33. Early Versus Late Intervention Trial With Estradiol (ELITE) study. http://clinicaltrials.gov/ct2/show/NCT00114517 (accessed 14 October 2010).
34. F. Grodstein, J.E. Manson, and M.J. Stampfer Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study Ann Intern Med 135 2001 1 8
35. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199 208 35
36. U. Pripp, G. Hall, and G. Csemiczky A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease J Hypertension 17 1999 1379 1386
37. F. Al-Khalili, B.M. Landgren, and S. Eksborg Does sublingual 17 beta-oestradiol have any effects on exercise capacity and myocardial ischaemia in post-menopausal women with stable coronary artery disease? Eur Heart J 19 1998 1019 1026
38. C.M. Webb, G.M. Rosano, and P. Collins Oestrogen improves exercise induced myocardial ischemia in women Lancet 351 1998 1556 1557
39. F. Al-Khalili, M. Eriksson, B.M. Landgren, and K. Schenck-Gustafsson Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women Am J Cardiol 82 1998 215 218
40. N. Cherry, K. Gilmour, and P. Hannaford Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial Lancet 360 2002 2001 2008
41. S.C. Clarke, J. Kelleher, and H. Lloyd-Jones A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study Br J Obstet Gynaecol 109 2002 1056 1062
42. P. Collins, M. Flather, and B. Lees WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators; randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study Eur Heart J 27 2006 2046 2053
43. S. Hulley, D. Grady, and T. Bush Vittinghoff E Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 611
44. D. Grady, D. Herrington, and V. Bittner HERSResearch Group. Cardiovascular disease outcomes during 6. 8 years of hormonetherapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 288 2002 49 57 (Pubitemid 34705518)
45. M. Canonico, E. Oger, G. Plu-Bureau, and J. Conard Estrogen and Thromboembolism Risk (ESTHER) Study Group Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study Circulation 115 2007 840 845
46. M. Canonico, and P.Y. Scarabin Hormone therapy and risk of venous thromboembolism among postmenopausal women Climacteric 12 Suppl. 1 2009 76 80